Talking Precision Medicine Najat Khan | Radical Transformation: Becoming a Medicines Company with End-to-End AI | TPM #44
Mar 28, 2025
Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion Pharmaceuticals, dives into the revolutionary impact of AI on drug discovery. She shares insights on how tech-driven biotech firms are transforming the pharmaceutical landscape. The discussion highlights the vital role of AI in clinical development and data integration for better patient outcomes. Exploring challenges and innovations, Najat emphasizes the need for a skilled workforce that bridges science and technology, paving the way for future biotech advancements.
AI Snips
Chapters
Transcript
Episode notes
Recursion Pharma's Evolution and Approach
- Recursion Pharma is a leader in AI-driven drug discovery, evolving from a tech-bio startup.
- It uses an end-to-end AI approach, from biological insight to clinical development.
Najat Khan's Role and Recursion's Mission
- Najat Khan's mandate is to integrate Recursion's platform for drug development, from biology to clinical trials.
- Recursion aims to create impactful medicines for patients by leveraging AI and interdisciplinary expertise.
Recursion's Strategic Partnerships and Acquisitions
- Recursion strategically partners and acquires to enhance its capabilities, avoiding a "not built here" attitude.
- Examples include Exscientia for AI and med chem, Farrow Health for trial design, and Tempus/Helix for patient stratification.